MedPage Today June 10, 2024
Ian Ingram

— Arexvy now approved for people 50 years and older at increased risk of serious outcomes

The FDA expanded the approval of GSK’s respiratory syncytial virus (RSV) vaccine (Arexvy) to include adults ages 50 to 59 at risk of RSV-related lower respiratory tract disease (LRTD) due to underlying conditions, the company announced on Friday.

Previously the adjuvanted RSV prefusion F protein-based vaccine had been approved only for adults 60 and older; it is currently recommended for use via shared decision-making by the CDC and Advisory Committee on Immunization Practices.

According to the vaccine maker, an estimated 13 million U.S. adults ages 50 to 59 years have medical conditions — e.g., asthma, chronic obstructive pulmonary disease, diabetes, heart failure — putting...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
STAT+: Trump’s FDA director pick has a history of criticizing the agency. Here are seven examples
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

Share This Article